Accessibility Menu
 
Camp4 Therapeutics logo

Camp4 Therapeutics

(NASDAQ) CAMP

Current Price$5.00
Market Cap$267.90M
Since IPO (2024)-52%
5 YearN/A
1 Year-6%
1 Month+27%

Camp4 Therapeutics Financials at a Glance

Market Cap

$267.90M

Revenue (TTM)

$3.50M

Net Income (TTM)

$80.40M

EPS (TTM)

$-2.57

P/E Ratio

-2.01

Dividend

$0.00

Beta (Volatility)

1.64 (High)

Price

$5.00

Volume

10,181

Open

$5.00

Previous Close

$5.00

Daily Range

$4.87 - $5.13

52-Week Range

$1.30 - $7.75

CAMP News

CAMP: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Camp4 Therapeutics

Industry

Biotechnology

Employees

48

CEO

Josh Mandel-Brehm, MBA

Headquarters

Cambridge, MA 02139, US

CAMP Financials

Key Financial Metrics (TTM)

Gross Margin

77%

Operating Margin

-15%

Net Income Margin

-23%

Return on Equity

-145%

Return on Capital

-51%

Return on Assets

-68%

Earnings Yield

-49.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$267.90M

Shares Outstanding

51.92M

Volume

10.18K

Short Interest

0.00%

Avg. Volume

195.95K

Financials (TTM)

Gross Profit

$1.86M

Operating Income

$52.06M

EBITDA

$50.42M

Operating Cash Flow

$29.55M

Capital Expenditure

$279.00K

Free Cash Flow

$29.83M

Cash & ST Invst.

$109.52M

Total Debt

$1.97M

Camp4 Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$348.00K

-46.6%

Gross Profit

$24.00K

-103.7%

Gross Margin

-6.90%

N/A

Market Cap

$267.90M

N/A

Market Cap/Employee

$4.87M

N/A

Employees

55

N/A

Net Income

$40.28M

-203.4%

EBITDA

$12.40M

+8.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$107.54M

+94.2%

Accounts Receivable

$155.00K

+43.5%

Inventory

$0.00

N/A

Long Term Debt

$1.69M

-69.7%

Short Term Debt

$286.00K

-90.7%

Return on Assets

-68.25%

N/A

Return on Invested Capital

-50.89%

N/A

Free Cash Flow

$6.29M

+154.5%

Operating Cash Flow

$6.29M

+155.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VXRTVaxart, Inc.
$0.63+0.03%
UNCYUnicycive Therapeutics, Inc.
$6.73-1.17%
ALXOALX Oncology Holdings Inc.
$2.18-0.46%
RPTXRepare Therapeutics Inc.
$2.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CMCSAComcast
$29.02+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
TAT&T
$28.31+0.02%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%

Questions About CAMP

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.